Thyroid gland disorder

Summary

Thyroid gland disorder (MONDO:0003240) is a disease (an umbrella term covering 12 Mondo subtypes) with 1 cohort gene (302 GWAS associations across 34 studies) and 132 clinical trials. Top therapeutic interventions include levothyroxine, cefazolin, and doxycycline anhydrous.

At a glance

• Umbrella term: 12 Mondo subtypes
• Cohort genes: 1
• GWAS associations: 302
• ClinVar variants: 1
• Clinical trials: 132

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thyroid gland disorder
Mondo ID	MONDO:0003240
EFO	EFO:1000627
MeSH	D013959
DOID	DOID:50
ICD-10-CM	E00-E07
NCIT	C26893
SNOMED CT	14304000
UMLS	C4317107
MedGen	1378579
Anatomy (UBERON)	UBERON:0002046
Is cancer (heuristic)	no

Also known as: disease of thyroid gland · disease or disorder of thyroid gland · disorder of thyroid gland · thyroid disease · thyroid gland disease · thyroid gland disease or disorder · thyroid gland diseases · thyroid gland disorder · thyroid gland disorders

Data availability: 1 ClinVar variant · 302 GWAS associations (34 studies).

Disease family

An umbrella term covering 12 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › thyroid gland disorder

Related subtypes (47): autoimmune disorder of endocrine system, parathyroid gland disorder, endocrine gland neoplasm, gonadal disorder, pancreas disorder, pituitary gland disorder, thymus gland disorder, liver disorder, adrenal gland disorder, hyperinsulinemic hypoglycemia, non-neoplastic bile duct disorder, endocrine tuberculosis, campomelic dysplasia, polycystic ovary syndrome, dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome, hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome, genito-palato-cardiac syndrome, hypoinsulinemic hypoglycemia and body hemihypertrophy, Bamforth-Lazarus syndrome, blepharophimosis - intellectual disability syndrome, SBBYS type, Wolfram-like syndrome, hypomyelinating leukodystrophy 8 with or without oligodontia and-or hypogonadotropic hypogonadism, estrogen resistance syndrome, short stature, microcephaly, and endocrine dysfunction, polyendocrinopathy, pituitary deficiency, hereditary endocrine growth disease, diencephalic syndrome, muscular pseudohypertrophy-hypothyroidism syndrome, neonatal iodine exposure, disorders of vitamin D metabolism, rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome, duplication of the pituitary gland, familial hypocalciuric hypercalcemia, hypothalamic adipsic hypernatraemia syndrome, Leydig cell hypoplasia, inherited obesity, beta thalassemia, thyroid hormone metabolism, abnormal, neuroendocrine disorder, NKX2-1 related choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction, parneoplastic endocrine syndrome, 17,20-lyase deficiency, isolated, 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete, 17-alpha-hydroxylase/17,20-lyase deficiency, combined partial, disorder of GNAS inactivation, acquired hypothalamic obesity

Subtypes (12): thyrocalcitonin secretion disease, thyroiditis, hyperthyroidism, thyroid malformation, hyperthyroxinemia, goiter, hypothyroidism, C-cell hyperplasia, atrophy of thyroid, euthyroid sick syndrome, thyroid tumor, inherited thyroid metabolism disease

Genetics & variants

GWAS landscape

302 GWAS associations across 34 studies. Top hits map to 12 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr6:32636375	3e-202		G	0.21
chr1:113834946	6e-184		G	0.32
chr9:97776641	5e-163		G	0.21
rs965513	9e-148	PTCSC2	A	0.23
rs7030241	3e-132	PTCSC2	T	0.23
chr12:111446804	2e-124		C	0.17
rs7850258	2e-119	PTCSC2	A	0.24
chr2:203874196	7e-97		A	0.15
rs6679677	5e-65	PHTF1 - RSBN1	C	0.22
rs9272293	7e-65	HLA-DQA1	A	0.22
rs3087243	2e-64	CTLA4 - ICOS	G	0.15
rs7310615	7e-63	SH2B3	C	0.14
rs3184504	4e-59	ATXN2, SH2B3	T	0.14
rs2476601	3e-58	AP4B1-AS1, PTPN22	A	0.24
rs3134996	1e-57	HLA-DQB1 - MTCO3P1	A	0.15
chr1:108357003	7e-55		T	0.24
chr1:108357797	5e-54		C	0.21
rs11675342	8e-54	TPO	C	0.13
rs17020127	1e-51	VAV3	A	0.23
rs78495697	3e-49	VAV3	C	0.2
chr3:188403231	3e-49		T	0.1
chr2:191090463	1e-48		T	0.12
chr1:107821014	2e-48		C	0.18
rs11211645	2e-44	TPO	A	0.12
chr6:90279406	4e-42		C	0.1
chr11:95578258	1e-40		C	0.12
chr4:148712316	2e-37		T	0.11
chr6:166972858	2e-34		C	0.09
chr10:6056861	7e-34		C	0.09
chr22:37190632	4e-33		C	0.09

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90473152	UK Biobank Whole-Genome Sequencing Consortium	2025	45,375	413,065	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667783	UK Biobank Whole-Genome Sequencing Consortium	2025	45,375	413,065	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90475276	Verma A	2024	33,335	282,333	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90038635	Donertas HM	2021	28,254	456,344	Common genetic associations between age-related diseases.
GCST90475277	Verma A	2024	26,295	289,373	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475654	Verma A	2024	4,240	438,790	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90727281	Kim HI	2026	4,054	39,972	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90477306	Verma A	2024	3,866	441,120	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476719	Verma A	2024	3,597	51,908	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479597	Verma A	2024	3,597	51,908	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	2
Tier 2: splice/UTR	0
Tier 3: regulatory	1
Tier 4: intronic/intergenic	47

MAF distribution

Bucket	Variants
common (>=0.05)	29
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	21

Functional consequences

Consequence	Count
unknown	27
intron_variant	13
intergenic_variant	4
non_coding_transcript_exon_variant	3
missense_variant	2
regulatory_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr6:32636375							3e-202	Tier 4: intronic/intergenic
chr1:113834946							6e-184	Tier 4: intronic/intergenic
chr9:97776641							5e-163	Tier 4: intronic/intergenic
rs965513	9	97793827	A>C,G,T	0.333	intron_variant	PTCSC2	9e-148	Tier 4: intronic/intergenic
rs7030241	9	97788093	T>A,C,G	0.321	non_coding_transcript_exon_variant	PTCSC2	3e-132	Tier 4: intronic/intergenic
chr12:111446804							2e-124	Tier 4: intronic/intergenic
rs7850258	9	97786731	A>G,T	0.322	non_coding_transcript_exon_variant	PTCSC2	2e-119	Tier 4: intronic/intergenic
chr2:203874196							7e-97	Tier 4: intronic/intergenic
rs6679677	1	113761186	C>A,T	0.096	intergenic_variant	PHTF1 - RSBN1	5e-65	Tier 4: intronic/intergenic
rs9272293	6	32635965	A>G,T	0.458	intergenic_variant	HLA-DQA1	7e-65	Tier 4: intronic/intergenic
rs3087243	2	203874196	G>A,T	0.446	intergenic_variant	CTLA4 - ICOS	2e-64	Tier 4: intronic/intergenic
rs7310615	12	111427245	C>A,G,T	0.49	intron_variant	SH2B3	7e-63	Tier 4: intronic/intergenic
rs3184504	12	111446804	T>A,C,G	0.491	missense_variant	ATXN2, SH2B3	4e-59	Tier 1: coding
rs2476601	1	113834946	A>G,T	0.081	missense_variant	AP4B1-AS1, PTPN22	3e-58	Tier 1: coding
rs3134996	6	32669089	A>C,T	0.361	non_coding_transcript_exon_variant	HLA-DQB1 - MTCO3P1	1e-57	Tier 4: intronic/intergenic
chr1:108357003				0.085			7e-55	Tier 4: intronic/intergenic
chr1:108357797				0.085			5e-54	Tier 4: intronic/intergenic
rs11675342	2	1403856	C>T	0.421	intron_variant	TPO	8e-54	Tier 4: intronic/intergenic
rs17020127	1	107815461	A>G	0.085	intron_variant	VAV3	1e-51	Tier 4: intronic/intergenic
rs78495697	1	107813097	C>A,T	0.086	intron_variant	VAV3	3e-49	Tier 4: intronic/intergenic
chr3:188403231							3e-49	Tier 4: intronic/intergenic
chr2:191090463							1e-48	Tier 4: intronic/intergenic
chr1:107821014							2e-48	Tier 4: intronic/intergenic
rs11211645	2	1408809	A>G,T	0.385	intron_variant	TPO	2e-44	Tier 4: intronic/intergenic
chr6:90279406							4e-42	Tier 4: intronic/intergenic
chr11:95578258							1e-40	Tier 4: intronic/intergenic
chr4:148712316							2e-37	Tier 4: intronic/intergenic
chr6:166972858							2e-34	Tier 4: intronic/intergenic
chr10:6056861							7e-34	Tier 4: intronic/intergenic
chr22:37190632							4e-33	Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
373954	NM_000094.4(COL7A1):c.1442G>A (p.Arg481His)	COL7A1	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
COL7A1	Orphanet:158673	Localized dystrophic epidermolysis bullosa, acral form
COL7A1	Orphanet:158676	Localized dystrophic epidermolysis bullosa, nails only
COL7A1	Orphanet:231568	Autosomal dominant generalized dystrophic epidermolysis bullosa
COL7A1	Orphanet:79408	Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form
COL7A1	Orphanet:79409	Recessive dystrophic epidermolysis bullosa inversa
COL7A1	Orphanet:79410	Localized dystrophic epidermolysis bullosa, pretibial form
COL7A1	Orphanet:79411	Self-improving dystrophic epidermolysis bullosa
COL7A1	Orphanet:89842	Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form
COL7A1	Orphanet:89843	Dystrophic epidermolysis bullosa pruriginosa

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
COL7A1	HGNC:2214	ENSG00000114270	Q02388	Collagen alpha-1(VII) chain	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
COL7A1	Collagen alpha-1(VII) chain	Stratified squamous epithelial basement membrane protein that forms anchoring fibrils which may contribute to epithelial basement membrane organization and adherence by interacting with extracellular matrix (ECM) proteins such as type IV c…

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	29.2×	0.034

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
COL7A1	Antibody/Immunoglobulin	yes		VWF_A, Kunitz_BPTI, FN3_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
skin of abdomen	1
skin of leg	1
stromal cell of endometrium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
COL7A1	267	ubiquitous	marker	stromal cell of endometrium, skin of abdomen, skin of leg

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
COL7A1	1,767

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
COL7A1	Q02388

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 10. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Anchoring fibril formation	1	761.3×	0.007	COL7A1
Fibronectin matrix formation	1	571.0×	0.007	COL7A1
Laminin interactions	1	380.7×	0.007	COL7A1
Cargo concentration in the ER	1	335.9×	0.007	COL7A1
Collagen chain trimerization	1	259.6×	0.007	COL7A1
Assembly of collagen fibrils and other multimeric structures	1	200.3×	0.007	COL7A1
Collagen degradation	1	175.7×	0.007	COL7A1
Collagen biosynthesis and modifying enzymes	1	170.4×	0.007	COL7A1
COPII-mediated vesicle transport	1	163.1×	0.007	COL7A1
Integrin cell surface interactions	1	134.3×	0.007	COL7A1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
endodermal cell differentiation	1	495.6×	0.006	COL7A1
epidermis development	1	210.7×	0.007	COL7A1
cell adhesion	1	37.5×	0.027	COL7A1

Therapeutics

Drugs indicated or in trials for this disease

4 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Carbimazole	Approved (phase 4)
Methimazole	Approved (phase 4)
Potassium Perchlorate	Approved (phase 4)
Propylthiouracil	Approved (phase 4)

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
COL7A1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	1	COL7A1
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
COL7A1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 132.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	103
PHASE4	7
PHASE3	7
PHASE2	6
PHASE1/PHASE2	3
PHASE1	3
PHASE2/PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06785987	PHASE4	ENROLLING_BY_INVITATION	Continuous Lidocaine Infusion in Thyroid Surgery Using Intraoperative Neurophysiological Monitoring
NCT07462195	PHASE4	RECRUITING	Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery
NCT01831869	PHASE4	UNKNOWN	Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism
NCT01848171	PHASE4	UNKNOWN	Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism
NCT03469310	PHASE4	COMPLETED	Minimizing Narcotic Analgesics After Endocrine Surgery
NCT04542278	PHASE4	COMPLETED	Preoperative Steroids in Autoimmune Thyroid Disease
NCT05294393	PHASE4	COMPLETED	Ropivacaine Plus Magnesium Sulphate Infiltration
NCT04785443	PHASE3	RECRUITING	Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy
NCT05276063	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
NCT06112340	PHASE2/PHASE3	RECRUITING	Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
NCT06752239	PHASE3	RECRUITING	Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
NCT01189292	PHASE3	COMPLETED	Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery
NCT01696305	PHASE3	COMPLETED	Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy
NCT02980679	PHASE3	COMPLETED	A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need Surgery
NCT05117853	PHASE3	UNKNOWN	Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy
NCT06036576	PHASE3	COMPLETED	Thyroxine Therapy for Recurrent Pregnancy Loss in Hypothyroid Women
NCT00054756	PHASE2	COMPLETED	Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
NCT00106119	PHASE2	COMPLETED	Thyroid and Glucose and Energy Metabolism
NCT01727973	PHASE1/PHASE2	COMPLETED	Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves’ Orbitopathy
NCT01873014	PHASE1/PHASE2	UNKNOWN	the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake
NCT02203682	PHASE2	UNKNOWN	Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
NCT03037385	PHASE1/PHASE2	COMPLETED	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT04124705	PHASE2	COMPLETED	A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
NCT04427904	PHASE2	UNKNOWN	Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery
NCT06054178	PHASE2	COMPLETED	Identification of Nerves Using Fluorescein Sodium
NCT03640247	PHASE1	COMPLETED	Pain Medications Following Thyroidectomy and Parathyroidectomy
NCT04842942	PHASE1	UNKNOWN	The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach
NCT06939946	PHASE1	TERMINATED	Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI)
NCT04094493	EARLY_PHASE1	UNKNOWN	Vit D Role in Post Thyroidectomy Hypocalcemia
NCT05635266	Not specified	RECRUITING	Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05678374	Not specified	RECRUITING	Exploring Immunological Markers Associated With Mental Fatigue in Graves’ Disease
NCT06296420	Not specified	RECRUITING	Dysphagia After Thyroidectomy
NCT06730321	Not specified	RECRUITING	Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)
NCT06738888	Not specified	RECRUITING	Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy
NCT06803732	Not specified	RECRUITING	Postoperative Pain of Robotic, Endoscopic and Open Lateral Neck Dissection
NCT06864351	Not specified	RECRUITING	Prospective Evaluation of OptiThyDose
NCT06868459	Not specified	ENROLLING_BY_INVITATION	Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry
NCT06960005	Not specified	ENROLLING_BY_INVITATION	ThyMoves: Screening and Exercise to Improve Muscle, Enhance Quality of Life, and Reduce Fall Risk in Thyroid Disease
NCT07027579	Not specified	NOT_YET_RECRUITING	Effect of Nutrition Education on the Quality of Life, Chronic Disease Adaptation in Patients With Thyroid Dysfunction
NCT07043166	Not specified	RECRUITING	Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEVOTHYROXINE	4	7
CEFAZOLIN	4	3
DOXYCYCLINE ANHYDROUS	4	2
INDOCYANINE GREEN ACID FORM	4	2
CALCIUM CARBONATE	4	1
FLUORESCEIN SODIUM	4	1
LIOTHYRONINE	4	1
PRALSETINIB	4	1
PROPYLTHIOURACIL	4	1
TRAMADOL	4	1
TRIAMCINOLONE	4	1
THYROID	3	7
LINSITINIB	3	2
CIPEPOFOL	3	1
CHEMBL4059722	0	1
CHEMBL4297597	0	1
CHEMBL1200433	0	1
(R,R)-TRAMADOL	0	1
CELLULOSE, OXIDIZED	-1	1